Inhibition of neutral endopeptidase, the degradative enzyme for natriuretic peptides, in rat kidney after oral SCH 42495

Clinical Science

Volumn 93, Issue 1, 1997, Pages 43-50

  Burrell, Louise M ^a   Farina, Nicole ^a   Risvanis, John ^a   Woollard, David ^a   Casely, David ^a   Johnston, Colin I ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

125I labelled RB104; Autoradiography; Neutral endopeptidase; SCH 42495

Indexed keywords

ATRIAL NATRIURETIC FACTOR; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRILAT; ENZYME INHIBITOR; IODINE 125; KIDNEY ENZYME; MEMBRANE METALLOENDOPEPTIDASE; N [2 (ACETYLTHIOMETHYL) 3 (2 METHYLPHENYL)PROPIONYL]METHIONINE ETHYL ESTER; PRODRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; ENZYME INHIBITION; ENZYME LOCALIZATION; FEMALE; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; NONHUMAN; ORAL DRUG ADMINISTRATION; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; PROTEIN DEGRADATION; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 0030878775     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/cs0930043     Document Type: Article

References (35)

1. Struthers AD. Ten years of natriuretic peptide research: a new dawn for their diagnostic and therapeutic use? Br Med J 1994; 308: 1615-9.
2. Maack T, Suzuki M, Almeida FA, et al. Physiological role of silent receptors of atrial natriuretic factor. Science 1987; 238: 675-8.
3. Kenny A, Stephenson SL. Role of endopeptidase-24.11 (enkephalinase) in the inactivation of atrial natriuretic peptide. FEBS Lett 1988; 232: 1-8.
4. Roques BP, Noble F, Dauge V, Fournie-Zaluski M-C, Beaumont A. Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology. Pharmacol Rev 1993; 45: 118-46.
5. Koepke J, Tyler L, Trapani A, et al. Interaction of non-guanylate cyclase-linked atriopeptin receptor ligand and endopeptidase inhibitor in conscious rats. J Pharmacol Exp Ther 1989; 249: 172-6.
6. Chiu PJ, Tetzloff G, Romano MT, Foster CJ, Sybertz EJ. Influence of C-ANF receptor and neutral endopeptidase on pharmacokinetics of ANF in rats. Am J Physiol 1991; 260: R208-16.
7. 125I-atrial natriuretic factor in anaesthetized rats: effects of neutral endopeptidase inhibition with candoxatrilat and of ANF-C receptor blockade. Biochem Pharmacol 1992; 44: 1013-22.
8. Charles CJ, Espiner EA, Nicholls G, et al. Clearance receptors and endopeptidase 24.11; equal role in natriuretic peptide metabolism in conscious sheep. Am J Physiol 1996; 271: R373-80.
9. Watkins RW, Vemulapalli S, Chiu PJ, et al. Atrial natriuretic factor potentiating and hemodynamic effects of SCH 42495, a new neutral metalloendopeptidase inhibitor. Am J Hypertens 1993; 6: 357-68.
10. Sybertz Jr EJ, Chiu PJS, Watkins RW, Vemulapalli S. Neutral metalloendopeptidase inhibition: a novel means of circulatory modulation. J Hypertens 1990; 8: S161-7.
11. Monopoli A, Forlani A, Ongini E. Chronic inhibition of neutral endopeptidase reduces left ventricular hypertrophy without changing blood pressure in spontaneously hypertensive rats. J Hypertens 1991; 9: S246-7.
12. Sala C, Monopoli A, Casati C, et al. Hemodynamic and humoral effects of chronic treatment with the neutral endopeptidase inhibitor SCH 42495 in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1994; 23: 703-8.
13. Thompson JS, Sheedy W, Morice AH. Effects of the neutral endopeptidase inhibitor, SCH 42495, on the cardiovascular remodelling secondary to chronic hypoxia in rats. Clin Sci 1994; 87: 109-14.
14. Davis HR, McGregor D, Hoos L, Mullins DE, Sybertz EJ. ANF and the neutral endopeptidase inhibitor, SCH 42495, prevent myointimal proliferation after vascular injury (Abstract). Circulation 1992; 84: 1-220.
15. Fettner SH, Pai S, Zhu GR, Kosoglou T, Banfield CR, Batra V. Pharmacokinetic-pharmacodynamic (PK-PD) modelling for a new antihypertensive agent (neutral metalloendopeptidase inhibitor SCH 42354) in patients with mild to moderate hypertension. Eur J Clin Pharmacol 1995; 48: 351-9.
16. Ogihara T, Rakugi H, Masuo K, Yu H, Nagano M, Mikami H. Antihypertensive effects of the neutral endopeptidase inhibitor SCH 42495 in essential hypertension. Am J Hypertens 1994; 7: 943-7.
17. Northridge DB, Alabaster CT, Connell JMC, et al. Effects of UK 69578: a novel atriopeptidase inhibitor. Lancet 1989; ii: 591-3.
18. 125I]RB104, a potent inhibitor of neutral endopeptidase 24.11, and its use in detecting nanogram quantities of the enzyme by 'inhibitor gel electrophoresis'. Proc Natl Acad Sci USA 1992; 89: 6388-92.
19. Kanazawa M, Johnston CI. Distribution and inhibition of neutral metalloendopeptidase (NEP) (EC 3.4.24.11), the major degradative enzyme for atrial natriuretic peptide, in the rat kidney. Clin Exp Pharmacol Physiol 1991; 18: 449-53.
20. Kanazawa M, Casley DJ, Sybertz EJ, Haslanger MF, Johnston CI. Localization and characterization of neutral metalloendopeptidase (EC 3.4.24.11), the degradative enzyme for atrial natriuretic peptide, in rat kidney using a radioiodinated neutral metalloendopeptidase inhibitor. J Pharmacol Exp Ther 1992; 261: 1231-7.
21. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin-phenol reagent. J Biol Chem 1951; 193: 265-75.
22. Florentin D, Sassi A, Roques BP. A highly sensitive fluorometric assay for 'enkephalinase', a neutral metalloendopeptidase that releases tyrosine-glycine-glycine from enkephalins. Anal Biochem 1984; 141: 62-9.
23. 125I-MK351A binding studies of plasma and tissue ACE during variation of salt status in rat. J Hypertens 1986; 4: 759-65.
24. Burrell LM, Palmer J, Charlton JA, Thomas T, Baylis PH. A new radioimmunoassay for human atrial natriuretic peptide and its physiological validation. J Immunoassay 1990; 11: 159-75.
25. Tsunoda K, Hodsman GP, Sumithran E, Johnston CI. Atrial natriuretic peptide in chronic heart failure in the rat. Circ Res 1986; 59: 256-61.
26. Johnston CI, Mendelsohn FAO, Casely DJ. Evaluation of renin and angiotensin assays and their clinical applications. Med J Aust 1971; I: 126-8.
27. Landry C, Santagata P, Bawab W, et al. Characterization of neutral endopeptidase 24.11 in dog glomeruli. Biochem J 1993; 291: 773-9.
28. Tikkanen I, Helin K, Tikkanen T, et al. Elevation of atrial natriuretic peptide in rats with chronic heart failure by SCH 39370, a neutral metallo-endopeptidase inhibitor. J Pharmacol Exp Ther 1990; 254: 641-5.
29. Pham I, El Amrani A-IK, Fournie-Zaluski M-C, Corvol P, Roques B, Michel J. Effects of the selective neutral endopeptidase inhibitor, retrothiorphan, on renal function and blood pressure in conscious normotensive Wistar and hypertensive DOCA-salt rats. J Cardiovasc Pharmacol 1992; 20: 847-57.
30. Burnier M, Ganslmayer M, Perret F, et al. Effects of SCH 34826, an orally active inhibitor of atrial natriuretic peptide degradation in healthy volunteers. Clin Pharmacol Ther 1991; 50: 181-91.
31. Richards A, Wittert G, Espiner E, Yandle T, Frampton C, Ikram H. Prolonged inhibition of endopeptidase 24.11 in normal man: renal, endocrine and haemodynamic effects. J Hypertens 1991; 9: 955-62.
32. Charles CJ, Espiner EA, Cameron VA, Richards AM, Yandle TG, Sybertz EJ. Hemodynamic and hormonal effects of neutral endopeptidase inhibitor SCH 39370 in sheep. Hypertension 1991; 17: 643-51.
33. Rademaker M, Charles CJ, Espiner EA, Nicholls M, Richards A, Kosoglou T. Neutral endopeptidase inhibition: augmented atrial and brain natriuretic peptide, haemodynamic and natriuretic responses in ovine heart failure. Clin Sci 1996; 91: 283-91.
34. Richards M, Espiner E, Frampton C, et al. Inhibition of endopeptidase EC 24.11 in humans: renal and endocrine effects. Hypertension 1990; 16: 269-76.
35. Schmitt F, Martinez F, Ikeni A, et al. Acute renal effects of neutral endopeptidase inhibition in humans. Am J Physiol 1994; 167: F20-7.